Pharmaceutical News

RSS

The Medical Letter introduces mobile apps for iPad, Android

The Medical Letter – recognized since 1959 as the most trusted source of unbiased prescription drug information and drug facts - announces the launch of its mobile apps for iPad, iPhone, iPod Touch and Android.

17 Mar 2012

Obesity appears to increase risk of mortality tied to sleeping pills

Obesity appears to significantly increase the risk of death tied to sleeping pills, nearly doubling the rate of mortality even among those prescribed 18 or fewer pills in a year, researchers reported Friday.

17 Mar 2012

Antibiotics may increase incidence and severity of allergic asthma in early life

Widely used antibiotics may increase incidence and severity of allergic asthma in early life, according to a University of British Columbia study.

17 Mar 2012

Adverse drug reactions could be avoided among adult hospital and emergency patients

Close to half of adverse reactions to medicines among adult hospital and emergency patients could be avoided, shows a study from the Nordic School of Public Health NHV.

16 Mar 2012

ThromboGenics, Alcon collaborate to commercialize ocriplasmin outside the US

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.

16 Mar 2012

Health Canada approves Mylan-Rosuvastatin Calcium Tablets

Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan Inc., today received approval from Health Canada for Mylan-Rosuvastatin Calcium Tablets, 5mg, 10mg, 20mg and 40mg. Mylan-Rosuvastatin is the generic version of Astra Zeneca's Crestor Tablets, which are used for the management of primary hypercholesterolaemia, mixed dyslipidaemia, and familial hypercholesterolaemia.

16 Mar 2012

Teva gets exclusive 180 days to market generic antidepressant and anti-anxiety pill Lexapro

Teva Pharmaceutical Industries Ltd. Has won U.S. approval to sell the first generic version of Lexapro for depression and anxiety. Teva has been granted a 180-day exclusivity, so no other firm can market the generic medication in the United States in that timeframe, the Food and Drug Administration (FDA) said in a news release.

15 Mar 2012

First-ever compulsory license issuance in India could have implications for HIV medication

"On Monday, the Indian Patent Office effectively ended German drug maker Bayer's monopoly for its cancer drug Nexavar and issued its first-ever compulsory license allowing local generic maker Natco Pharma to make and sell the drug cheaply in India," Reuters reports.

15 Mar 2012

Anti-inflammatory drugs may offer novel treatment for CHD

A large international study indicates that anti-inflammatory drugs may become a new tool for preventing and treating coronary heart disease (CHD), the leading global cause of death.

15 Mar 2012

New study suggests another benefit to antimicrobial stewardship

Curbing unnecessary use of antibiotics is our best defense against the spread of drug-resistant infections. A new study suggests another benefit to antimicrobial stewardship: a potential cost savings of millions of dollars now wasted on therapies that don't help patients.

15 Mar 2012

Mobile phones could play a valuable role in helping HIV patients to take medication every day

Mobile phones could play a valuable role in helping HIV patients to take their medication every day, according to a new Cochrane Systematic Review. The researchers found that patients were less likely to miss doses if they were sent weekly mobile phone text message reminders.

15 Mar 2012

New position paper outlines national approach to antimicrobial stewardship

As the supply of life-saving antibiotics becomes increasingly threatened, infectious diseases experts urge healthcare systems and policymakers to step up efforts to protect patients by preserving the effectiveness of available antibiotics through antimicrobial stewardship initiatives.

15 Mar 2012

NCH to expand outpatient methadone education program

Carl Backes, Jr., MD, a neonatologist and current cardiology fellow at Nationwide Children's Hospital, has been awarded $35,000 from the March of Dimes Ohio Chapter for his project to expand an outpatient methadone education program.

15 Mar 2012

AT-1001 shows promise in treating drug addiction

In preclinical studies, researchers at SRI International and Astraea Therapeutics have recently evaluated the role of a new drug receptor target that shows promise for the treatment of drug addiction.

15 Mar 2012

Largest-ever study of community-wide TB drug prevention did not improve TB control in South African mines

"After seven years of research, the world's largest study of preventative tuberculosis (TB) therapy has found that untargeted, community-wide distribution of TB prevention drugs did not improve TB control in South African gold mines," PlusNews reports.

15 Mar 2012

Teva commences commercial launch of Escitalopram Oxalate Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commenced commercial launch of Escitalopram Oxalate Tablets, the Company's generic version of Forest Laboratories' depression and generalized anxiety disorder treatment, Lexapro Tablets.

15 Mar 2012

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.

15 Mar 2012

Scientists identify new compound that quickly kills HCC cells

Scientists have identified a new compound that rapidly kills hepatocellular carcinoma (HCC) cells, the most common form of liver cancer and fifth most common cancer worldwide, while sparing healthy tissue.

15 Mar 2012

EffRx receives FDA approval for BINOSTO to treat osteoporosis

EffRx Pharmaceuticals SA today announced that the U.S. Food and Drug Administration (FDA) has approved BINOSTO (alendronate sodium) Effervescent Tablets, previously known as EX101, for the treatment of osteoporosis in postmenopausal women, and as a treatment to increase bone mass in men with osteoporosis. EffRx anticipates that BINOSTO will be commercially available in the United States in the third quarter of 2012.

15 Mar 2012

Publicly available profile of effects of approved and investigational medicines

The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant testing systems, NIH announced today.

14 Mar 2012